Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
MEDI-528
Known as:
Anti-IL9 Monoclonal Antibody MEDI-528
, MEDI 528
, MEDI-528, anti-IL-9 antibody
National Institutes of Health
Create Alert
Related topics
Related topics
1 relation
Broader (1)
Antibodies, Monoclonal, Humanized
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
From bench to bedside: Therapeutic potential of interleukin-9 in the treatment of asthma.
Fang Gong
,
Yu-hong Pan
,
X. Huang
,
H. Zhu
,
D. Jiang
Experimental and therapeutic medicine
2017
Corpus ID: 21889428
Initially identified as a T cell and mast cell growth factor, interleukin (IL)-9 has long been recognized as an important…
Expand
2017
2017
Targeting cytokines in asthma therapy: could IL-37 be a solution?
M. Wegmann
Expert review of respiratory medicine
2017
Corpus ID: 27115523
Patients suffering from bronchial asthma display a number of symptoms including productive coughing, wheezing, chest tightness…
Expand
Highly Cited
2013
Highly Cited
2013
A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma
C. Oh
,
R. Leigh
,
K. McLaurin
,
K. Kim
,
M. Hultquist
,
N. Molfino
Respiratory Research
2013
Corpus ID: 6117918
BackgroundPreclinical studies suggest that interleukin-9 may be a central mediator in the development and maintenance of airway…
Expand
Highly Cited
2011
Highly Cited
2011
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma
J. Parker
,
C. Oh
,
+7 authors
N. Molfino
BMC pulmonary medicine
2011
Corpus ID: 15622039
BackgroundInterleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo…
Expand
2010
2010
MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma.
S. Antoniu
Current opinion in molecular therapeutics
2010
Corpus ID: 23088594
In development by MedImmune LLC, under license from Genaera Corp, MEDI-528 is an injectable, humanized mAb against IL-9 for the…
Expand
2010
2010
Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2A Study To Evaluate The Effect Of A Humanized Interleukin-9 Monoclonal Antibody (MEDI-528) On Exercise-induced Bronchospasm
J. M. Parker
,
S. Brazinsky
,
+5 authors
N. Molfino
ATS
2010
Corpus ID: 75792366
2010
2010
Monoclonal antibody therapy directed against interleukin-9: MEDI-528
A. Humbles
,
J. L. Reed
,
+4 authors
A. Coyle
2010
Corpus ID: 70358369
Highly Cited
2009
Highly Cited
2009
Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
B. White
,
F. León
,
W. White
,
G. Robbie
Clinical therapeutics
2009
Corpus ID: 23354553
BACKGROUND Interleukin-9 (IL-9) is involved in pathogenic aspects of the asthmatic response, including induction of the…
Expand
2009
2009
A candidate gene association study of 77 polymorphisms in migraine.
M. Schuerks
,
T. Kurth
,
J. Buring
,
R. Y. Zee
The journal of pain : official journal of the…
2009
Corpus ID: 29545904
UNLABELLED Population-based studies have established an association between migraine and cardiovascular disease (CVD). We sought…
Expand
2007
2007
A SINGLE DOSE OF MEDI-528, A MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-9, IS WELL TOLERATED IN MILD AND MODERATE ASTHMATICS IN THE PHASE II TRIAL MI-CP-138
P. O'Byrne
,
L. Boulet
,
G. Gauvreau
,
F. León
,
S. Sari
,
Barbara White
2007
Corpus ID: 72354040
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE